Clinical-stage radiopharmaceutical company Oncoinvent ASA (Euronext Growth Oslo:ONCIN) on Monday announced updated 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis.
The trial, which closed for recruitment at the end of 2023, is now in long-term follow-up.
In the study, 10 patients received a single intraperitoneal dose of 7 MBq Radspherin. At the 12-month follow-up reported in November 2024, only one patient had experienced peritoneal recurrence.
The 18-month data showed no new recurrences, maintaining the recurrence rate at 10%. In comparable populations treated with best standard of care, approximately 40% of patients would typically have had a recurrence by this stage.
Aqemia and Sanofi expand drug discovery collaboration with new research target
Camurus' FDA accepts CAM2029 NDA resubmission for acromegaly, sets December decision date
Raidium introduces AI-powered oncology imaging workflow for US cancer centres
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
MAXONA Pharmaceuticals' Phase 2 clinical trial IND application for MAX-001 cleared by US FDA
Kalohexis presents dual MC3R/MC4R activation data at ICO 2026
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
Bruker expands infection diagnostics portfolio with DISQVER platform acquisition
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint